Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection (DOT-H): an Open-label, Randomized, Controlled Study.

NCT07555431 is registered in ClinicalTrials.gov with Carlos Brites as lead sponsor.

NCT NCT07555431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07555431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection (DOT-H): an Open-label, Randomized, Controlled Study.
Lead sponsor
Carlos Brites
Phase
Phase 2
Overall status
Recruiting
Start date
May 7, 2026
Completion date
June 30, 2028
Enrollment
146 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

htlv i associated myelopathies, htlv i associated t cell leukemia lymphoma, htlv-1 infection, neuritis